PTPN11 and neoplasm: Among the targets being investigated for combined benefit with KRASG12C inhibitors, SHP2 inhibitors have gained interest due to their ability to impact both tumor cell autonomous MAPK signaling and JAK-STAT signaling, as well as regulation of T cell receptor signaling (6, 9, 14, 15, 21, 52, 53).